Investor Open Day Highlights at Zylox-Tonbridge
Recently, Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190), an esteemed leader in neurovascular and peripheral vascular interventional solutions, hosted its Investor Open Day at the Zhuhai Innovation Center. This engaging event attracted almost 150 institutional investors and analysts eager to learn more.
The day was a showcase of the company's strategic vision aimed at developing a competitive vascular intervention platform. By focusing on research and development, global-scale manufacturing, and an expanding commercial presence, Zylox-Tonbridge is setting itself up for sustained growth. Attendees experienced presentations, product demonstrations, and guided tours of the facility, providing a thorough insight into the company's comprehensive innovation and operational strategies.
Innovative Solutions for Endovascular Care
Zylox-Tonbridge presented an impressive range of both commercialized and near-market products. This portfolio reflects the robustness and competitiveness of its endovascular solutions for both neurovascular and peripheral applications.
Among the standout innovations were:
- ZYLOX Mammoth™ Large-Bore Thrombectomy Catheter, recognized as China’s only 12F–18F peripheral thrombectomy catheter. It is uniquely designed with a proprietary flared tip that enhances the efficiency of clot removal in deep vein thrombosis cases.
- Feilong™ Embolization Assist Stent, which is the first to adopt DFT (Drawn Filled Tubing) braided technology in China. This advanced design ensures complete radiopacity for improved precision during procedures.
The company also spotlighted its image-guided endovascular therapy platform, featuring its intravascular optical coherence tomography (OCT) system alongside the ZYLOX Pantheris™ atherectomy catheter. This fascinating technology is the only one available commercially that offers real-time visualization for plaque removal in peripheral arteries, marking a significant leap towards precision-based interventions that align with global standards of care.
Synchronizing Innovation and Global Expansion
During discussions, Zylox-Tonbridge’s management shared insights about scaling operations through integrated product innovation, advanced manufacturing, and an international marketing strategy. This holistic approach is designed to propel the company forward in a competitive landscape.
Dr. Jonathon Zhong Zhao, the Chairman and CEO, emphasized the mission to establish Zylox-Tonbridge as a top-tier global vascular intervention platform. He stated that the combination of meaningful innovations with a growth-ready manufacturing backbone and a broad international infrastructure fosters sustainable global expansion.
By 2025, the use of Zylox-Tonbridge's products is projected to surpass one million procedures, indicating strong acceptance and adoption among treating physicians.
As part of its global strategy, Zylox-Tonbridge is making rapid strides. By year-end 2025, the company plans to have its products available in 83 countries while nurturing partnerships with over 80 distributors worldwide. The focus remains on fortifying its global operational framework, including regulatory compliance, manufacturing efficiency, and market execution to support organic growth and strategic international expansion in key medtech markets.
About Zylox-Tonbridge
Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190) is dedicated to medical innovation, focusing on developing, manufacturing, and commercializing medical devices for vascular interventions. Established in 2012 and headquartered in Hangzhou, China, Zylox-Tonbridge is an integrated medical technology enterprise powered by robust in-house R&D and manufacturing capabilities, proprietary technology systems, and strong sales networks.
The company is committed to its mission of "Innovation for Quality Life," striving to deliver high-quality, affordable healthcare solutions that enhance wellness for patients everywhere.
Frequently Asked Questions
What was the purpose of Zylox-Tonbridge's Investor Open Day?
The Investor Open Day aimed to inform institutional investors and analysts about Zylox-Tonbridge's strategic vision, innovation pipeline, and growth plans.
What notable products were showcased during the event?
Zylox-Tonbridge highlighted products like the ZYLOX Mammoth™ thrombectomy catheter and the Feilong™ embolization assist stent, showcasing advanced medical technology.
How is Zylox-Tonbridge expanding globally?
The company plans to broaden its reach into 83 countries and enhance partnerships with distributors to facilitate international growth.
What is Zylox-Tonbridge's commitment to innovation?
Zylox-Tonbridge is dedicated to enhancing healthcare through research, development, and providing quality medical devices to improve patient outcomes.
How does Zylox-Tonbridge support healthcare quality?
With its philosophy of "Innovation for Quality Life," the company aims to deliver state-of-the-art medical devices that are both effective and affordable for patients worldwide.
